Skip to main content

Table 4 Summary of the results of laboratory analysis

From: Patient safety and public health concerns: poor dissolution rate of pioglitazone tablets obtained from China, Myanmar and internet sites

Sampling Site Year Test Test (n/%)
Originator Brand Generic Total samples, n
Compliant Non-compliant Compliant Non-compliant
China (Shanghai) 2012 Potency 9/100 0/0 34/97 1/3 44
Content Uniformity 9/100 0/0 35/100 0/0
Dissolution 9/100 0/0 35/100 0/0
Personal import samples 2013 Potency 19/100 0/0 13/100a 13/100a 59
Content Uniformity 19/100 0/0 13/100a 13/100a
Dissolution 19/100 0/0 8/62a 5/38a
Yangon, Myanmar 2015 Potency 1/100 0/0 59/98 1/2 60
Content Uniformity 1/100 0/0 59/98 1/2
Dissolution 1/100 0/0 51/86 8/14
Total number of samples, n 163
  1. aAmong the n = 31 generic samples, only 13 samples could be fully tested, as the number of tablets was insufficient